Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $232,349.00 in Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 17,873 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $13.00, for a total value of $232,349.00. Following the completion of the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at $1,172,340. This trade represents a 16.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Wednesday, July 1st, Raphi Levy sold 2,127 shares of Alpha Tau Medical stock. The stock was sold at an average price of $13.02, for a total value of $27,693.54.
• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total transaction of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Stock Performance

Shares of NASDAQ:DRTS traded up $0.30 on Monday, reaching $13.53. The company’s stock had a trading volume of 823,853 shares, compared to its average volume of 584,996. The stock’s 50-day moving average is $9.85 and its two-hundred day moving average is $7.91. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. The stock has a market capitalization of $1.22 billion, a P/E ratio of -20.13 and a beta of 1.17. Alpha Tau Medical Ltd. has a 52-week low of $2.87 and a 52-week high of $14.11.

Alpha Tau Medical (NASDAQ:DRTS) last posted its quarterly earnings data on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). As a group, sell-side analysts forecast that Alpha Tau Medical Ltd. will post -0.67 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. LADENBURG THALM/SH SH lifted their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Citigroup upped their price target on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Piper Sandler increased their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research report on Tuesday, May 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Finally, Zacks Research downgraded Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 1st. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Alpha Tau Medical currently has a consensus rating of “Hold” and an average target price of $12.60.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DRTS. Mariner LLC grew its position in shares of Alpha Tau Medical by 1.6% in the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after purchasing an additional 1,915 shares during the period. Trifecta Capital Advisors LLC acquired a new stake in Alpha Tau Medical in the 4th quarter worth about $48,000. Envestnet Asset Management Inc. acquired a new stake in Alpha Tau Medical in the 3rd quarter worth about $62,000. Wells Fargo & Company MN grew its holdings in Alpha Tau Medical by 291.7% in the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after buying an additional 17,500 shares during the period. Finally, Principal Financial Group Inc. purchased a new stake in Alpha Tau Medical in the 1st quarter valued at about $132,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.